CPRX Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Date	Price Target	Rating	Analyst
2/4/2025	$28.00	Outperform	Robert W. Baird
11/18/2024	$35.00	Overweight	Stephens
3/14/2024	$27.00	Buy	Citigroup
3/7/2024	$23.00	Buy	BofA Securities
12/21/2023	$30.00	Outperform	Oppenheimer
8/24/2022	$10.00 → $15.50	Buy → Neutral	ROTH Capital
2/8/2022	$9.00 → $12.00	Buy	HC Wainwright & Co.

Catalyst Pharmaceuticals Inc.

Peers

Recent Analyst Ratings for Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Strategy Officer Sundaram Preethi sold $103,649 worth of shares (3,924 units at $26.41), decreasing direct ownership by 9% to 41,081 units (SEC Form 4)

Chairman of Board of Directors Mcenany Patrick J sold $5,217,338 worth of shares (200,000 units at $26.09), decreasing direct ownership by 4% to 4,281,702 units (SEC Form 4)

New insider Andrews William T. claimed no ownership of stock in the company (SEC Form 3)

President and CEO Daly Richard J increased direct ownership by 54% to 199,764 units (SEC Form 4)

Chief Med. & Reg. Officer Ingenito Gary exercised 244,000 shares at a strike of $3.64 and sold $5,775,720 worth of shares (244,000 units at $23.67) (SEC Form 4)

Chief Med. & Reg. Officer Ingenito Gary exercised 225,000 shares at a strike of $2.24 and sold $4,894,610 worth of shares (225,000 units at $21.75) (SEC Form 4)

Chief Compliance/Legal Officer Elsbernd Brian exercised 62,525 shares at a strike of $2.24 and sold $1,446,933 worth of shares (62,975 units at $22.98) (SEC Form 4)

Chief Commercial Officer Del Carmen Jeffrey sold $696,382 worth of shares (30,423 units at $22.89), closing all direct ownership in the company (SEC Form 4)

Amendment: New insider Russo Gregg claimed no ownership of stock in the company (SEC Form 3)

New insider Russo Gregg claimed no ownership of stock in the company (SEC Form 3)